| Chemical Properties | Back Directory | [Boiling point ]
538.114±45.00 °C(Press: 760.00 Torr)(predicted) | [density ]
1.087±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | [solubility ]
DMF: 50 mg/ml; DMSO: 50 mg/ml; Ethanol: 50 mg/ml; PBS (pH 7.2): 1 mg/ml | [form ]
Liquid | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Description]
13,14-dihydro-15-keto-Prostaglandin E2-d9 (13,14-dihydro-15-keto PGE2-d9) is intended for use as an internal standard for the quantification of 13,14-dihydro-15-keto PGE2 by GC- or LC-MS. 13,14-dihydro-15-keto PGE2 is a metabolite of PGE2 and the primary PGE2 metabolite in plasma.1,2 It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase.2 Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery.3 Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).4 | [Uses]
13,14-Dihydro-15-keto-PGE2-d9 is the deuterium labeled 13,14-Dihydro-15-keto-PGE2[1]. | [References]
1. Hamberg, M., and Samuelsson, B. On the metabolism of prostaglandins E1 and E2 in man J. Biol. Chem. 246(22),6713-6721(1971).
2. Nishigaki, N., Negishi, M., and Ichikawa, A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist Mol. Pharmacol. 50(4),1031-1037(1996).
3. Husslein, P., and Sinzinger, H. Concentration of 13,14-dihydro-15-keto-prostaglandin E2 in the maternal peripheral plasma during labour of spontaneous onset Br. J. Obstet. Gynaecol. 91(3),228-231(1984).
4. Hughes, D., Otani, T., Yang, P., et al. NAD+-dependent 15-hydroxyprostaglandin dehydrogenase regulates levels of bioactive lipids in non-small cell lung cancer Cancer Prev. Res. (Phila.) 1(4),241-249(2008). |
|
|